Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 7/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | FDPS | P14324 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 7/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7817926 | 0.73 | FDPS (0.40) | MEN1KMT2AFDPSTSHRHTT | |
| SCHEMBL13916698 | 0.72 | FDPS (0.44) | MEN1KMT2AFDPSTSHRHTT | |
| SCHEMBL7731124 | 0.70 | CYP19A1 (0.46) | CYP19A1CYP17A1 | |
| SCHEMBL3979171 | 0.70 | FDPS (0.43) | MEN1KMT2AFDPSTSHRHTT | |
| SCHEMBL28147170 | 0.70 | — | — | |
| SCHEMBL27581291 | 0.69 | CYP19A1 (0.60) | CYP19A1MEN1KMT2ACYP17A1 | |
| Hydrochloric Acid SCHEMBL16540554 | 0.69 | TSHR (0.43) | MEN1KMT2AFDPSTSHRHTT | |
| SCHEMBL3577553 | 0.68 | CYP11B1 (0.50) | CYP19A1 | |
| SCHEMBL21153907 | 0.67 | FDPS (0.41) | MEN1KMT2AFDPSTSHR | |
| SCHEMBL6242617 | 0.67 | FDPS (0.45) | MEN1KMT2AFDPSTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7268230-B2 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2007-09-11 | — | — | US | disclosed |
| US-20050085465-A1 | Angiogenesis inhibitor; antiarthritic agents; psoriasis; anticancer agents | ASTRAZENECA AB (SE) | 2005-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085465-A1 | Angiogenesis inhibitor; antiarthritic agents; psoriasis; anticancer agents | VEGFA, FLT4, FLT1 | CYP19A1 847/4885MEN1 1947/4885KMT2A 3259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.